CliffBio
biologic

Obizur

Antihemophilic Factor (Recombinant), Porcine Sequence

Loss of exclusivityOctober 2026projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameObizur
Active ingredientAntihemophilic Factor (Recombinant), Porcine Sequence
Strength500U
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2014
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Obizur patent cliff — loss of exclusivity October 2026 | CliffBio